Home/Pipeline/NCE Candidate 3

NCE Candidate 3

Undisclosed

Discovery/PreclinicalActive

Key Facts

Indication

Undisclosed

Phase

Discovery/Preclinical

Status

Active

Company

Alembic Pharmaceuticals

About Alembic Pharmaceuticals

Alembic Pharmaceuticals' mission is to accelerate access to quality, affordable medicines globally through a vertically integrated model spanning API synthesis to finished dosage forms. The company has achieved significant scale, with over $250M in annual US frontend sales, a pipeline of 252 ANDA filings, and a strategic foray into proprietary drug discovery with three disclosed NCE candidates. Its strategy balances cash-generating generics businesses with disciplined R&D investments in complex generics and novel therapeutics to drive long-term, high-margin growth.

View full company profile

Therapeutic Areas

Anti-infectives Cardiology Neurology Gastroenterology Dermatology Oncology

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active